Literature DB >> 9067293

Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.

M Tan1, J Yao, D Yu.   

Abstract

Overexpression of the c-erbB-2 gene-encoded p185 has been reported in approximately 30% of human breast cancers and has been correlated with lymph node metastasis and poor prognosis in breast cancer patients. To investigate whether overexpression of p185 can enhance the metastatic potential of human breast cancer cells, we have introduced the human c-erbB-2 gene into the very low p185-expressing MDA-MB-435 human breast cancer cells and established 435.eB transfectants that express higher levels of p185. In this study, we compared the metastatic phenotypes of the parental MDA-MB-435 cells and the 435.eB transfectants. In vivo experimental metastasis assays in which we injected MDA-MB-435 parental cells or 435.eB transfectants into the tail veins of ICR-SCID mice demonstrated that mice injected with p185-overexpressing 435.eB transfectants formed significantly more metastatic tumors than the mice injected with parental and control cells. The changes in experimental metastatic potential in vivo were accompanied by increased invasiveness in vitro. In addition, the secretion of basement membrane-degradative enzymes, which is an important step in the invasion and metastasis process, was also increased in the p185-overexpressing 435.eB transfectants. These results indicated that p185 overexpression can enhance the metastatic potential of MDA-MB-435 human breast cancer cells. To investigate whether enhanced metastatic potential in the p185-overexpressing 435.eB transfectants was the result of increased cancer cell growth and transformation potential, we compared the growth rate, anchorage-independent growth ability, and tumorigenicity of the 435.eB transfectants with that of the parental cells. The transfectants and the parental cells all had similar growth rates and anchorage-independent growth abilities and demonstrated similar tumorigenic potential. These findings suggest that c-erbB-2 is a metastasis-promoting gene for breast cancers that is distinct from other tumor-promoting genes in that the c-erbB-2 gene can enhance the intrinsic metastatic potentials of MDA-MB-435 cells without increasing their transformation abilities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067293

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

Review 1.  Mediterranean diet, olive oil and cancer.

Authors:  Ramón Colomer; Javier A Menéndez
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

2.  Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables.

Authors:  J Decock; W Hendrickx; H Wildiers; M R Christiaens; P Neven; M Drijkoningen; R Paridaens
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells.

Authors:  Guogang Yuan; Lu Qian; Lun Song; Ming Shi; Dan Li; Ming Yu; Meiru Hu; Beifen Shen; Ning Guo
Journal:  Mol Cell Biochem       Date:  2008-07-04       Impact factor: 3.396

4.  Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells.

Authors:  Alessandra Pincini; Giusy Tornillo; Francesca Orso; Marianna Sciortino; Brigitte Bisaro; Maria Del Pilar Camacho Leal; Antonio Lembo; Maria Felice Brizzi; Emilia Turco; Cristiano De Pittà; Paolo Provero; Enzo Medico; Paola Defilippi; Daniela Taverna; Sara Cabodi
Journal:  Cell Cycle       Date:  2013-06-28       Impact factor: 4.534

Review 5.  Antibody-based imaging of HER-2: moving into the clinic.

Authors:  R E Wang; Y Zhang; L Tian; W Cai; J Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

6.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

Review 7.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

8.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth.

Authors:  Pei He; Dan Zhu; Jun-Jian Hu; Ju Peng; Lian-Sheng Chen; Guang-Xiu Lu
Journal:  Mol Biol Rep       Date:  2009-05-15       Impact factor: 2.316

10.  Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.

Authors:  Gang Niu; Zibo Li; Qizhen Cao; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.